New Drug Reviews

Umeclidinium (Incruse Ellipta) for COPD


Am Fam Physician. 2017 Jan 15;95(2):120-121.

Umeclidinium inhalation powder (Incruse Ellipta) is a long-acting anticholinergic medication labeled for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis.1

 Enlarge     Print

DrugDosageDose formCost*

Umeclidinium (Incruse Ellipta)

One inhalation (62.5 mcg) daily; no titration required

Inhaler preloaded with one-dose blisters of dry powder medication


*—Estimated retail price of one month's treatment based on information obtained at (accessed November 3, 2016).

DrugDosageDose formCost*

Umeclidinium (Incruse Ellipta)

One inhalation (62.5 mcg) daily; no titration required

Inhaler preloaded with one-dose blisters of dry powder medication


*—Estimated retail price of one month's treatment based on information obtained at (accessed November 3, 2016).


Umeclidinium is a relatively safe medication with few systemic adverse effects. As with aclidinium (Tudorza Pressair), umeclidinium powder contains lactose and should not be used by patients with severe milk protein allergy because anaphylactic reactions have been reported. Similar to other anticholinergic medications, umeclidinium can theoretically cause paradoxical bronchospasm, urinary retention, and cardiac effects.1 Adverse effects with umeclidinium monotherapy are similar to those of umeclidinium combined with an inhaled corticosteroid and a long-acting beta-2 adrenergic agonist.1 Trials assessing adverse effects for umeclidinium included a relatively small number of patients (n = 576) and are therefore underpowered for rare but potentially important harms. Umeclidinium has not been studied in pregnant women, and it is unknown whether it is excreted in breast milk. It is a pregnancy risk category C.1


Umeclidinium is fairly well tolerated. The most common adverse effects are nasopharyngitis (8% vs. 7% with placebo), upper respiratory tract infection (5% vs. 4%), cough (3% vs. 2%), and arthralgia (2% vs. 1%).1 In clinical trials, the drop-out rate was 7%, compared with 4% of the placebo group in the primary efficacy trial, and was mostly related to a pulmonary disorder (3%), infection (1%), or a cardiac event (2%).2 Some patients may feel that the powder has an unpleasant lactose taste.


Umeclidinium is at least as effective as tiotropium (Spiriva) for the treatment of COPD symptoms in patients with moderate to severe disease. Umeclidinium improves quality of life as demonstrated by a decreased score on the St. George's Respiratory Questionnaire.3 It also improves patient-reported dyspnea as measured by the Transition Dyspnea Index.4 These clinically relevant symptom improvements are similar to those of tiotropium.3 Umeclidinium delays the time to first COPD exacerbation compared with placebo (hazard ratio = 0.61; 95% confidence interval, 0.41 to 0.90).3 Umeclidinium also provides improvement in trough forced expiratory volume in one second (FEV1) from baseline when combined with an inhaled corticosteroid with or without a long-acting beta agonist. However, studies evaluating FEV1 changes with umeclidinium alone are lacking.3,5 There is no research on umeclidinium's long-term effects on frequency of exacerbations, hospitalizations, and mortality in patients with COPD, and umeclidinium has not been studied in patients with asthma.


The average price of umeclidinium is $315 per month. It is less expensive than other long-acting anticholinergic inhalers (e.g., tiotropium, $360) and long-acting beta agonists (e.g., salmeterol [Serevent Diskus], $340). However, umeclidinium may be a higher-tier medication on certain health plans (typically tier 3 or 4), resulting in a higher co-pay, and it is not covered by all insurance plans.


The recommended dosage of umeclidinium is one 62.5-mcg inhalation daily. The administration device is preloaded with blisters of dry powder medication, requiring no user preparation. Each dose is automatically loaded when the user opens the lid until hearing a click. There is no dose adjustment required for patients with renal or hepatic impairment.

Bottom Line

Umeclidinium is an easy-to-use, once-daily, well-tolerated, and relatively low-cost anti-cholinergic agent for maintenance therapy in patients with moderate to severe COPD. It is at least as effective as tiotropium and improves dyspnea, quality of life, and FEV1, although its role among the current COPD maintenance therapies is unclear. It should be considered a first-line long-acting anti-cholinergic agent for moderate to severe COPD, especially for patients who cannot afford tiotropium or use it appropriately.

Address correspondence to R. Christopher Durigan, PharmD, BCPS, at Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.


show all references

1. DailyMed. Drug label information: Incruse Ellipta—umeclidinium aerosol, powder. Research Triangle Park, N.C.: GlaxoSmithKline; 2016. Accessed June 18, 2016....

2. Center for Drug Evaluation and Research. Medical review. Umeclidinium. 2013. Accessed June 18, 2016.

3. Pleasants RA, Wang T, Gao J, Tang H, Donohue JF. Inhaled umeclidinium in COPD patients: a review and meta-analysis. Drugs. 2016;76(3):343–361.

4. Ismaila AS, Huisman EL, Punekar YS, Karabis A. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:2495–2517.

5. Feldman G, Maltais F, Khindri S, et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:719–730.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

The series is coordinated by Allen F. Shaughnessy, PharmD, MMedEd, Contributing Editor.

A collection of STEPS published in AFP is available at



Copyright © 2017 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

More in AFP

More in Pubmed


Nov 2021

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article